Multiple Sclerosis Research Studies
Enrolling Trials
TG1101-RMS401/Enhance: Evaluating efficacy when transitioning from a current Disease Modifying Therapy (DMT) to ublituximab (ENHANCE)
Sponsor: TG Therapeutics, Inc.
Phase 3b
Active Subjects: 2
Principal Investigator: Jessica L. Stulc, M.D.
Studies in Follow-Up
GN41791/Fentrepid: A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrelizumab in Adult Patients with Primary Progressive Multiple Sclerosis
Sponsor: F. Hoffman-La-Roche
Phase: 3
Active Subjects: 5
Principal Investigator: Jessica L. Stulc, M.D.
OBS13434/Lemtrada Pass: A prospective, Multicenter, Observational, Post-Authorization Safety Study to Evaluate the Long-Term Safety Profile of LEMTRADA® (Alemtuzumab) Treatment in Patients with Relapsing
Forms of Multiple Sclerosis
Sponsor: Sanofi
Phase: 4
Active Subjects: 2
Principal Investigator: Jessica L. Stulc, M.D.
BA39731/Verismo: An Observational Study of Ocrelizumab Treated Patients with Multiple Sclerosis to Determine the Incidence and Mortality Rates of Breast Cancer and all Malignancies
Sponsor: F. Hoffman-La-Roche
Phase: 4
Active Subjects: 45
Principal Investigator: Jessica L. Stulc, M.D.
MS700568_0079/Master 2: An Observational Evaluation of Effectiveness and Patient-Reported Outcomes in Suboptimally Controlled Patients Previously Taking Oral or Infusion Disease-Modifying Drugs for Relapsing Forms of Multiple Sclerosis
Sponsor: EMD Serono
Phase: 4
Active Subjects: 1
Principal Investigator: Jessica L. Stulc, M.D.
LTS17043/Hercules Extension: An interventional, Phase 3 extension study to investigate long-term safety and tolerability of tolebrutinib in participants with relapsing multiple sclerosis, primary progressive multiple sclerosis, or nonrelapsing secondary progressive multiple sclerosis
Sponsor: Sanofi
Phase: 3
Active Subjects: 2
Principal Investigator: Jessica L. Stulc, M.D.
MN43964/Olero: A Multicenter, Single-Aim, Open-Label, Extension, Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab in Patients with Multiple Sclerosis
Sponsor: F. Hoffman-La-Roche
Phase: 3
Active Subjects: 3
Principal Investigator: Jessica L. Stulc, M.D.
Note: If you have any patients that could potentially qualify for any enrolling trials, please contact Jenna Skinner Jenna.skinner@Mpls-clinic.com or Dr. Jessica Stulc.
